论文部分内容阅读
作者从1985年6月1988年3月,采用α-2b-干扰素膀胱内灌注治疗85例膀胱原位癌。病人按用药量大小分为二组。A组(高剂量组):47例,每次灌注α-2b-干扰素量为100百万单位。B组(低剂量组):38例,每次灌注α-2b-干扰素量为10百万单位。二组病人均每周灌注一次,12周后改为每月-次,持续1年。在首次灌干扰素后3、6、9、和12个月作尿液和膀胱冲洗液细胞学检查,膀胱镜检+活检。疗效标准为;显效:细胞学检查和膀胱镜检+活检均阴性。有效:细胞学检查阳性,膀胱镜检+活检阴性,无效:细胞学检查和膀胱镜检+活检均为阳性。恶化:复发或新长肿瘤的分级和/或分期增加。作者发现显效者;A组20例(43%);B组2例
From June 1985 to March 1988, 85 patients with bladder carcinoma in situ were treated with intravesical instillation of α-2b-interferon. According to the size of the patient divided into two groups. Group A (high dose group): 47 patients, each infusion of α-2b-interferon was 100 million units. Group B (low dose group): 38 patients, each infusion of α-2b-interferon was 10 million units. Two groups of patients were perfusion weekly, 12 weeks later changed to monthly - for 1 year. Urine and bladder fluid cytology, cystoscopy + biopsy were performed 3, 6, 9, and 12 months after the first dose of interferon. Efficacy standards; markedly effective: Cytology and cystoscopy + biopsy were negative. Valid: Cytology positive, cystoscopy + biopsy negative, invalid: Cytology and cystoscopy + biopsy are positive. Deterioration: Grading and / or staging of recurrent or new long tumors. The authors found that markedly effective; A group of 20 patients (43%); B group of 2 patients